posted by Medis89

Adventrx Pharmaceuticals Incorporated engages in the in-licensing, development and commercialization of cancer-related proprietary drug therapies. According to Business Insights’ Cancer Market Outlook report, the market for cancer-related drug therapies and related products and services is expected to reach $40.9 billion by 2012. The market is large enough for a small pharmaceutical to eat a small piece of this huge pie and make a fortune for its investors in the process.

The company’s business model involves taking market share from big pharma by reformulating existing drugs, thereby extending the life cycle of revenue from large upfront investments deployed in the past by these same big pharma names. The trend toward reformulation in the pharmaceutical industry has grown substantially, which approached 45% of existing drugs undergoing testing for reformulation during the 2002 to 2005 period. That’s ANX’s business.

The company has focused upon its chemotherapy drugs ANX-530 and ANX-514 to dethrone well-established drugs Navelbine and Taxotere as means for taking the company’s business model to the next level. The lure of the company’s technologies rests upon the patient/doctor decision to choose an effective therapy to fight the disease of cancer, with compelling factors in the decision centered upon expected results, potential complications and side-effects during the treatment regime. The company has shown that ANX-530 and ANX-514 are more patient-friendly during the treatment process.

Many patients chose not to undergo the suffering caused by chemotherapy and do not survive cancer. Adventrx seeks to mute the discomfort of the recovery process to health. And if Carl Icahn’s opinion is of any import to an investor’s decision whether to invest in a small-cap pharmaceutical such as ANX, you’ll be glad to know that insider and institutional reports reveal that he’s taken both a professional and personal stake in the company.